Mechanisms and Key Molecular Target of Gentamacin Toxicity

庆大霉素毒性机制和关键分子靶点

基本信息

  • 批准号:
    8762413
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-10-01 至 2015-09-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abstract: Aminoglycoside antibiotics remain main line therapy for gram negative infections and are used in conjunction with other antibiotics for certain gram positive organisms. Unfortunately, they still have an unacceptably high rate of causing acute neprhotoxicity especially in the elderly and in patients with chronic kidney disease, heart and liver disorders. We have previously identified a nonnephrotoxic, yet bactericidal, congener of gentamicin that we now propose to use to determine the intracellular determinants of toxicity in proximal tubule cells in vivo in the rat model of aminoglycoside toxicity. We will build on our previous data where we identified Arf1 as a major upstream cytosolic target of gentamicin leading to intracellular trafficking defects using the power of yeast genetics. Using complimentary yeast and rat studies of gentamicin toxicity we will determine the biochemical, molecular and cell biologic mechanisms of Arf1 dysregulation by gentamicin and the protective benefit of the nontoxic gentamicin congener. Three specific aims will directly test the following hypothesis: We hypothesize that aminoglycoside antibiotics, following endocytic uptake and cytosolic release, interact directly with cytoplasmic proteins such as Arf1 to mediate cellular toxicity. We further hypothesize that these aminoglycoside-protein interactions rapidly alter intracellular trafficking processes in renal proximal tubule cells (PTCs) by altering the properties of identifiable molecular targets and that this in turn results in PTC dysfunction and ultimately nephrotoxicity. The nontoxic congener will allow us to directly compare and contrast intracellular differences between toxic and nontoxic forms thereby leading to greater understanding of the factors mediating the cytotoxic process. Finally, we will use siRNA to directly probe target molecules as we have previously demonstrated with p53 in proximal tubule cells using siRNA in rats.
描述(由申请人提供): 摘要:氨基糖苷类抗生素仍然是革兰氏阴性菌感染的主要治疗药物,并与其他抗生素联合用于某些革兰氏阳性菌。不幸的是,它们仍然具有不可接受的高比率引起急性肾毒性,特别是在老年人和患有慢性肾脏疾病、心脏和肝脏疾病的患者中。我们以前已经确定了一个非肾毒性,但杀菌,庆大霉素的同源物,我们现在建议使用,以确定在近端小管细胞内的毒性决定因素在体内的大鼠模型中的氨基糖苷类毒性。我们将建立在我们以前的数据,其中我们确定Arf 1作为庆大霉素的主要上游胞质靶点,使用酵母遗传学的力量导致细胞内运输缺陷。使用庆大霉素毒性的互补酵母和大鼠研究,我们将确定Arf 1失调的生化,分子和细胞生物学机制,由庆大霉素和无毒庆大霉素同源物的保护效益。三个具体的目标将直接测试以下假设:我们假设,氨基糖苷类抗生素,内吞摄取和胞质释放后,直接与细胞质蛋白,如Arf 1介导的细胞毒性。我们进一步假设,这些氨基糖苷类-蛋白质相互作用通过改变可识别的分子靶点的性质迅速改变肾近端小管细胞(PTC)的细胞内运输过程,这反过来又导致PTC功能障碍并最终导致肾毒性。无毒同系物将使我们能够直接比较和对比细胞内的差异之间的有毒和无毒的形式,从而导致更好地了解介导的细胞毒性过程的因素。最后,我们将使用siRNA直接探测靶分子,正如我们先前在大鼠近端小管细胞中使用siRNA证明的那样。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce A Molitoris其他文献

Technology Insight: biomarker development in acute kidney injury—what can we anticipate?
技术洞察:急性肾损伤中的生物标志物开发——我们可以期待什么?
  • DOI:
    10.1038/ncpneph0723
  • 发表时间:
    2008-01-29
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Bruce A Molitoris;Vyacheslav Y Melnikov;Mark D Okusa;Jonathan Himmelfarb
  • 通讯作者:
    Jonathan Himmelfarb

Bruce A Molitoris的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce A Molitoris', 18)}}的其他基金

Mechanisms and Key Molecular Target of Gentamacin Toxicity
庆大霉素毒性机制和关键分子靶点
  • 批准号:
    8141638
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8537445
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8447794
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms and Key Molecular Target of Gentamacin Toxicity
庆大霉素毒性机制和关键分子靶点
  • 批准号:
    8391642
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8917198
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8334637
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8731203
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States
疾病状态下的近曲小管白蛋白转运
  • 批准号:
    8235552
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Proximal Tubule Albumin Transport in Disease States.
疾病状态下的近端小管白蛋白转运。
  • 批准号:
    9309881
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms and Key Molecular Target of Gentamacin Toxicity
庆大霉素毒性机制和关键分子靶点
  • 批准号:
    8598026
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了